Whales with a lot of money to spend have taken a noticeably bullish stance on Guardant Health.
Looking at options history for Guardant Health (NASDAQ:GH) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 80% of the investors opened trades with bullish expectations and 10% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $213,680 and 5, calls, for a total amount of $238,740.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $75.0 for Guardant Health over the recent three months.
Analyzing Volume & Open Interest
In today's trading context, the average open interest for options of Guardant Health stands at 2435.0, with a total volume reaching 6,008.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Guardant Health, situated within the strike price corridor from $60.0 to $75.0, throughout the last 30 days.
Guardant Health Call and Put Volume: 30-Day Overview
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GH | CALL | TRADE | BULLISH | 01/16/26 | $2.25 | $1.9 | $2.2 | $75.00 | $59.4K | 2.8K | 1.3K |
| GH | PUT | TRADE | BULLISH | 09/19/25 | $3.5 | $3.1 | $3.2 | $60.00 | $54.7K | 2.0K | 248 |
| GH | CALL | TRADE | BULLISH | 01/16/26 | $2.25 | $1.25 | $2.1 | $75.00 | $51.0K | 2.8K | 851 |
| GH | CALL | TRADE | BULLISH | 01/16/26 | $2.2 | $1.8 | $2.1 | $75.00 | $48.7K | 2.8K | 1.0K |
| GH | CALL | TRADE | BULLISH | 01/16/26 | $2.15 | $1.7 | $2.1 | $75.00 | $47.4K | 2.8K | 455 |
About Guardant Health
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Current Position of Guardant Health
- Currently trading with a volume of 660,442, the GH's price is down by 0.0%, now at $55.4.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 49 days.
What Analysts Are Saying About Guardant Health
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $70.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from BTIG persists with their Buy rating on Guardant Health, maintaining a target price of $70.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Guardant Health with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
